ESSA Pharma (EPI) Stock Price, News & Analysis

Company Overview

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: C$7.33 to C$8.20
• 50-Day Range: C$8.20 to C$8.20
• 52-Week Range: C$4.00 to C$11.34
• Volume: 1,430 shs
• Average Volume: 4,834 shs
• Market Capitalization: C$237.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: CVE:EPI
• CIK: N/A
• Web: essapharmaceuticals.com
• Phone: +1-778-3310962
• Fax: N/A
• Employees: 25
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 37.29
• Quick Ratio: 36.72

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$2.21 per share
• Price / Cash Flow: 3.72
• Book Value: C$2.21 per share
• Price / Book: 3.72

Miscellaneous

• Outstanding Shares: 29,009,000
• Free Float: N/A
• Market Cap: C$237.87 million
• Optionable: Not Optionable
• Beta: N/A